The product is th e first- to -market generic for Voltaren ® Gel
Bridgewater, New Jersey (USA), March 24, 2016 – Amneal Pharmaceuticals LLC today announced the launch of its first-to-market generic equivalent of Voltaren® Gel (diclofenac sodium topical gel) 1% in the United States. Amneal recently received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for the product.
Amneal’s diclofenac sodium topical gel 1% is available in a 100g tube and is now shipping through wholesalers, distributors and directly to the trade.
“We are very pleased to be the first generic supplier of diclofenac sodium topical gel,” said Chirag Patel, Co-Chairman and Co-CEO. “This significant milestone continues to demonstrate our ability to bring complex dosage forms to our customers and patients, and generate savings to the healthcare system.”
According to IMS Health, the U.S. sales of diclofenac sodium topical gel were approximately $413 million, for the 12 months ending January 2016.
Click here for full prescribing information.
About Amneal Pharmaceuticals LLC
Amneal Pharmaceuticals LLC is a global supplier of generic pharmaceuticals, vertically-integrated across the entire supply chain from R&D to finished goods. Since its inception in 2002, Amneal has invested extensively in R&D resources, manufacturing infrastructure, and strategic expansion opportunities—all contributing to its significant growth. The Company prides itself on its unwavering commitment to quality, strong business relationships, and innovative approach to maximizing value. Amneal is privately-held with U.S. headquarters in Bridgewater, New Jersey and international headquarters in Zug, Switzerland. For more information, please visit www.amneal.com.
All trademarks are property of their respective owners.
Laurene IsipAmneal Pharmaceuticals LLC T: 908.409.6819 email@example.com